MAPT and frontotemporal dementia: Despite this result, since targeted protein degraders can affect degradation of their substrates at sub-stoichiometric cellular concentrations, we proceeded with testing the compound series in FTD patient iPSC-derived neuronal models to determine ability to change tau levels in ex vivo neurons.